Browse the evidence

Soy protein promotes gains in muscle mass and strength during resistance exercise training similarly to whey and other animal proteins, despite acute studies showing whey stimulates muscle protein synthesis more strongly.

If you are lifting weights, you do not need to buy whey protein. Soy protein works just as well for building muscle and strength over time. Focus on getting enough total protein from your diet, whether from soy, meat, or other sources.

Early combination therapy with new hypoglycemic drugs (SGLT-2i, GLP-1RA, or DPP-4i) achieves glycemic control faster and provides longer-lasting benefits compared to traditional stepwise monotherapy in prediabetes and type 2 diabetes.

If you have Type 2 Diabetes or prediabetes, starting with a combination of modern drugs (like SGLT-2 inhibitors, GLP-1 agonists, or DPP-4 inhibitors) alongside metformin is often more effective than starting with just one drug. This approach helps you reach healthy blood sugar levels faster and keeps them there longer, reducing the need to change treatments frequently. Discuss this strategy with your doctor to see if it fits your specific health profile and insurance coverage.

GLP-1 receptor agonists (e.g., semaglutide, tirzepatide) and SGLT-2 inhibitors are preferred medications for obesity management in patients with cardiovascular or metabolic risk, as they promote weight loss and improve cardiovascular health.

If you have obesity and diabetes or heart disease risk, ask your doctor about GLP-1 agonists (like semaglutide) or SGLT-2 inhibitors. These medications help you lose weight and protect your heart, unlike some other diabetes drugs that might cause weight gain.

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) such as semaglutide and tirzepatide are effective for weight loss in people with HIV, with tirzepatide showing the largest mean percent change in weight.

If lifestyle changes are not enough to manage weight gain from HIV medication, ask your doctor about GLP-1 RAs like semaglutide or tirzepatide. These drugs are highly effective for weight loss and can help reduce fat deposits. They are used alongside diet and exercise.

GLP-1 receptor agonists (semaglutide 2.4 mg) and other pharmacological interventions (liraglutide, orlistat) significantly reduce body weight and cardiovascular risk factors in obese patients, with semaglutide showing superior weight loss compared to placebo.

For obese individuals without diabetes, high-dose semaglutide (2.4 mg) can achieve substantial weight loss (approx. 15%) compared to placebo, which may improve cardiovascular risk factors. This is a viable option when lifestyle changes are insufficient.

Moderate-to-vigorous physical activity (MVPA) performed during morning hours (06:00–12:00) significantly reduces the risk of developing diabetic retinopathy (DR) and slows retinal thinning, whereas late-night physical activity increases DR risk.

If you have diabetes or are at risk, aim for at least 150 minutes of moderate-to-vigorous exercise per week. Crucially, try to schedule these workouts in the morning (between 6 AM and 12 PM). This timing appears to offer the strongest protection against diabetic eye disease. Avoid exercising late at night (midnight to 6 AM), as this may increase your risk.

Tirzepatide (10 mg and 15 mg) achieves statistically equivalent total body weight loss to sleeve gastrectomy (SG), with both interventions demonstrating superior efficacy compared to other pharmacotherapies.

If you are an adult with obesity, high-dose Tirzepatide (10-15 mg weekly) can help you lose approximately 21% of your body weight, which is statistically the same amount of weight loss achieved by sleeve gastrectomy surgery. This makes it a highly effective non-surgical option, though it requires weekly injections and lifestyle modifications.

Once-daily oral semaglutide 50 mg significantly reduces ad libitum energy intake, body weight, and appetite while improving control of eating in adults with obesity, without delaying gastric emptying at steady state.

Take oral semaglutide 50 mg once daily, following the specific dose-escalation schedule (starting at 1.5 mg and increasing every 4 weeks). Do not eat or drink (except water) for 6 hours before taking the tablet, and wait 30-45 minutes after taking it before your first meal. This regimen significantly reduces your energy intake and body weight primarily by lowering appetite and improving control over eating, rather than by slowing down your digestion.

Tirzepatide (5, 10, and 15 mg once weekly) produces significantly greater weight loss than both placebo and GLP-1 receptor agonists (semaglutide, dulaglutide) in adults with overweight or obesity.

If you have overweight or obesity, tirzepatide (administered once weekly) is a highly effective pharmacological option for weight loss, outperforming both placebo and existing GLP-1 medications like semaglutide. Expect significant weight reduction (up to ~12.5 kg with the highest dose) and a higher likelihood of achieving major weight loss milestones (5%, 10%, 15%). Be prepared for potential gastrointestinal side effects (nausea, diarrhea), which are common but often manageable and comparable to other drugs in this class. Consult a healthcare provider to determine if you are a candidate based on your BMI and health status.

Once-weekly tirzepatide (5, 10, or 15 mg) combined with lifestyle intervention produces statistically significant and clinically meaningful body weight reductions (up to -22.4%) and improvements in cardiometabolic risk factors in Japanese adults with obesity or overweight.

For Japanese adults with obesity or overweight, adding once-weekly tirzepatide to a standard lifestyle program (calorie deficit and exercise) leads to substantial weight loss (up to ~22%) and improves heart health markers like blood pressure and cholesterol. While injections are required, side effects like nausea are common but usually mild and temporary. This treatment is specifically approved and effective for this demographic, who may face higher health risks at lower BMIs compared to other ethnicities.

A 12-week low-glycemic index (LGI) diet produces significantly greater reductions in waist circumference, LDL cholesterol, non-HDL cholesterol, and leptin, along with greater increases in GLP-1, compared to a matched low-energy diet (LED) in women with excess body weight, without causing a decline in resting metabolic rate.

To improve your metabolic health and reduce belly fat, switch to a low-glycemic index diet for 12 weeks. Focus on eating foods with a GI of 55 or less freely, limit moderate-GI foods to two servings a day, and avoid high-GI foods. You do not need to strictly count calories; eat until you are satisfied. This approach has been shown to lower bad cholesterol, reduce belly fat more effectively than standard dieting, and improve hormonal markers like GLP-1 without slowing down your metabolism.

GLP-1 receptor agonists (liraglutide, semaglutide) and dual GIP/GLP-1 agonists (tirzepatide) produce significant weight loss in adults with obesity by acting centrally to reduce appetite and peripherally to delay gastric emptying.

Semaglutide 2.4mg weekly, combined with a 500 kcal daily deficit and 150 minutes of weekly activity, produces an average 14.8% body weight loss over 68 weeks. Expect gastrointestinal side effects like nausea, which are common but often manageable.

GLP-1 receptor agonists (GLP-1RAs) significantly reduce HbA1c levels and body weight in patients with type 2 diabetes and obesity, with efficacy increasing from single agonists to dual (GLP-1/GIP) and triple (GLP-1/GIP/glucagon) agonists.

GLP-1 based medications (single, dual, and triple agonists) are highly effective for treating type 2 diabetes and obesity. They work by mimicking hormones that regulate blood sugar and appetite. Newer dual and triple agonists (like Tirzepatide and Retatrutide) show greater improvements in blood sugar and weight loss than older single-agonist drugs. Treatment is typically chronic, as stopping the medication often leads to weight regain. Options include weekly or daily injections, and some oral formulations are available for those who prefer to avoid needles. Consult a doctor to determine the best agent and dose for your specific health profile.

Combining amylin receptor agonist (cagrilintide) with GLP-1 RA (semaglutide) results in greater weight reduction than semaglutide monotherapy.

Combining cagrilintide 2.4 mg and semaglutide 2.4 mg, both injected once weekly, leads to 17.1% body weight loss over 20 weeks, which is significantly better than semaglutide alone (9.8%).

High-dose GLP-1 receptor agonists (specifically semaglutide 2.4 mg) combined with lifestyle interventions produce significant, sustainable weight loss (-14.9% body weight) and improved glycemic control in patients with diabesity, making them superior to insulin and other antidiabetic agents regarding weight management.

If you have both diabetes and obesity, ask your doctor about GLP-1 agonists like semaglutide (2.4 mg). This treatment, combined with diet and exercise changes, has been shown to help patients lose nearly 15% of their body weight over 68 weeks while also controlling blood sugar. It is often more effective for weight loss than insulin, which tends to cause weight gain. Be aware that you might experience some nausea or vomiting at first, but these symptoms usually go away, and the long-term health benefits are significant.

The Mediterranean diet reduces visceral adiposity and insulin resistance, key drivers of metabolic syndrome.

Focus on reducing visceral fat by following a Mediterranean diet rich in fiber and healthy fats. This helps improve insulin sensitivity and reduces the risk of metabolic syndrome, even if total body weight changes are gradual.

GLP-1 receptor agonists (specifically liraglutide and semaglutide) produce the greatest weight loss among anti-diabetic medications, with effects classified as strong (>5% reduction), whereas DPP-4 inhibitors and alpha-glucosidase inhibitors (acarbose) produce only mild or neutral effects.

If you have Type 2 Diabetes and struggle with weight loss, GLP-1 receptor agonists (like liraglutide or semaglutide) are currently the most effective pharmacological option for reducing body weight, significantly outperforming older drugs like DPP-4 inhibitors or acarbose. While these drugs may cause initial gastrointestinal side effects, their ability to produce strong weight loss (>5%) makes them a superior choice for managing obesity in diabetic patients compared to weight-neutral or weight-gain-inducing alternatives like sulfonylureas or insulin.

GLP-1 receptor agonists (GLP-1 RAs) promote weight loss and improve glycemic control through multiple mechanisms including increased satiety, slowed gastric emptying, and enhanced insulin secretion, with semaglutide 2.4 mg showing the highest efficacy.

GLP-1 receptor agonists like semaglutide are highly effective for weight loss and blood sugar control. Semaglutide 2.4 mg taken once weekly (either orally or by injection) resulted in an average loss of 15.3 kg over 68 weeks in clinical trials. This is significantly more effective than placebo. These drugs work by increasing satiety, slowing digestion, and improving insulin function. They are suitable for adults with obesity or type 2 diabetes.

Tirzepatide 15 mg provides superior HbA1c reduction and bodyweight loss compared to other GLP-1RA-based therapies, including high-dose GLP-1RA and GLP-1RA plus basal insulin fixed-ratio combinations, without increasing the risk of hypoglycemia.

For patients with type 2 diabetes seeking maximum glycemic control and weight loss, tirzepatide 15 mg is the most effective GLP-1RA-based therapy available, outperforming high-dose GLP-1RAs and insulin combinations without increasing hypoglycemia risk.

Tirzepatide, a dual GIP/GLP-1 receptor agonist, achieves greater glycemic control and weight loss compared to isolated GLP-1 receptor agonism.

For individuals with Type 2 Diabetes or obesity who need more than standard GLP-1 medications, Tirzepatide is a newer option that targets two hormone receptors (GIP and GLP-1). Clinical trials show it can lower blood sugar by more than 2% and achieve weight loss exceeding 15%, which is greater than what is typically seen with GLP-1-only drugs.

Tirzepatide, a dual GIP/GLP-1 receptor agonist, induces substantial weight loss and improves histological markers of metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis in patients with type 2 diabetes and obesity.

If you have MASH and obesity, tirzepatide is a once-weekly injection that helps you lose weight and improves liver health markers. It starts at a low dose and increases slowly to minimize side effects. You should also follow diet and exercise advice provided by your care team.

Tirzepatide produces significantly greater weight loss and glycemic improvement than semaglutide when used at comparable maintenance dosages and adherence levels.

If you are choosing between Semaglutide and Tirzepatide, Tirzepatide tends to produce greater weight loss (approx. 12% vs 8% average in this study). However, this benefit is only realized if you stay on the medication. If you struggle with side effects or cost, switching drugs may not solve the problem if you end up discontinuing.

Consuming protein and/or fiber before carbohydrates (meal sequencing) enhances GLP-1 secretion, delays gastric emptying, and improves postprandial glucose and lipid metabolism compared to consuming carbohydrates first.

To get more out of your meals, try eating your protein and vegetables before your carbohydrates (like rice, pasta, or bread). This simple change in order triggers your gut to release more satiety hormones (GLP-1) and slows down digestion, leading to better blood sugar control and less fat storage potential.

Prevention or delay of type 2 diabetes through intensive lifestyle intervention or metformin is associated with a lower prevalence of microvascular complications (retinopathy, nephropathy, neuropathy) compared to those who progress to diabetes.

Avoiding or delaying the onset of type 2 diabetes significantly reduces your risk of developing serious microvascular complications like eye, kidney, and nerve damage. This benefit is observed even if you don't take medication, as long as you prevent or delay diabetes.